Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00271323
Other study ID # XRP6976B_2507
Secondary ID EudraCT #: 2005-
Status Terminated
Phase Phase 2
First received December 29, 2005
Last updated December 21, 2009
Start date May 2005
Est. completion date February 2007

Study information

Verified date December 2009
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

- Primary : To determine the safety profile of each treatment group.

- Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date February 2007
Est. primary completion date February 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Informed consent form obtained, signed and dated before specific protocol procedures.

2. Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma or a combination of these)

3. Patients must have a loco regionally advanced unresectable NSCLC;

- Stage IIIA with clinical multiple N2 nodes (preferably with histological or cytological confirmation).

- Patients with peripheral tumours of the lower lobe with contralateral upper mediastinal nodes at station N2 are excluded·

- Stage IIIB T4 or N3.

- In the T4 category, patients with pleural or pericardial effusion and multiple nodules in the same lobe are excluded.

- Patients with T4 disease secondary to extensive and massive involvement of the great vessels are excluded.Patients should be excluded when the expected risk of pulmonary toxicity is likely to be high, e.g. V20 in excess of 35%.

4. Males or females aged between 18 and 75 years.

5. Life expectancy of at least 12 weeks.

6. WHO performance status 0 or 1.

7. Weight loss <=10% within the last 3 months.

8. Laboratory requirements at entry (within 7 days before randomization):

- Blood cell counts:

- Absolute neutrophils >= 2.0 x 10^9/L

- Platelets >= 100 x 10^9/L

- Hemoglobin >= 10 g/dl

- Renal function:

- Serum creatinine <=1 x the upper limit of normal (UNL). In case of borderline value of serum creatinine, the 24h creatinine clearance should be >= 60 mL/min.

- Hepatic function:

- Serum bilirubin <= 1 x UNL

- ASAT and ALAT <= 2.5 x UNL

- Alkaline phosphatase <= 5 x UNL Patients with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase> 2.5 x UNL are not eligible for the study.

9. Lung function tests at entry:

- FEV1: >= 50 % x Normal value

- DLCO: >= 50 % x Normal value

10. Adequate cardiac function.

11. Patient with either measurable and/or non-measurable lesion (according to RECIST criteria).

Exclusion Criteria:

1. Diagnosis of small cell lung cancer.

2. Pregnant or lactating women.

3. Patients (male or female) with reproductive potential not implementing adequate contraceptive measures.

4. Prior systemic chemotherapy, immunotherapy, or biological therapy including neoadjuvant or adjuvant treatment for NSCLC.

5. Prior surgery for NSCLC, if less than 5 years from study.

6. Prior radiotherapy for NSCLC.

7. History of prior malignancies, except for cured non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years.

8. Symptomatic peripheral neuropathy Grade >= 2 except if due to trauma.

9. Other serious concomitant illness or medical conditions:

- Congestive heart failure or angina pectoris except if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias.

- History of significant neurological or psychiatric disorders including dementia or seizures.

- Active infection requiring IV antibiotics.

- Active ulcer, unstable diabetes mellitus or other contra-indication to corticosteroid therapy.

- Superior vena cava syndrome contra-indicating hydration.

- Preexisting pericardial effusion.

- Preexisting symptomatic pleural effusion.

10. Significant gastrointestinal abnormalities, including requirement for intravenous nutrition, active peptic ulcer disease, prior surgical procedures affecting absorption.

11. Distant metastasis.

12. Concurrent treatment with any other experimental anti-cancer drugs.

13. Concomitant or within 4-week period administration of any other experimental drug under investigation.

14. Significant ophthalmologic abnormalities.

15. Moderate to severe dermatitis.

16. Hypersensitivity to docetaxel, cisplatin, or any of its excipients.

17. Concomitant use of phenytoin, carbamazepin, barbiturates, or rifampicin.

18. Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.

19. Patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to return for follow-up visits, and not likely to complete the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
docetaxel and cisplatin
Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
Radiation:
radiotherapy
Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.

Locations

Country Name City State
France Sanofi-Aventis Paris

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary overall response rate in population of patients eligible and evaluable for response No
Primary time to progression from the date of start treatment until progression No
Primary duration of response only on responders No
See also
  Status Clinical Trial Phase
Completed NCT00985855 - Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer Phase 2
Completed NCT01048645 - Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer Phase 2
Completed NCT00129844 - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Phase 2
Completed NCT00098085 - Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04995523 - A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC Phase 1/Phase 2
Completed NCT00910676 - Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors Phase 2
Withdrawn NCT00108186 - Celecoxib Treatment for Lung Cancer Phase 1
Recruiting NCT05037825 - The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Recruiting NCT00379717 - Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Completed NCT00404924 - ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Phase 3
Completed NCT00102505 - A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT02905591 - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Phase 2
Active, not recruiting NCT03088540 - Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 3
Terminated NCT00232206 - Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer Phase 2
Completed NCT00037817 - Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies Phase 1
Completed NCT03444766 - Study of Nivolumab for Advanced Cancers in India Phase 4
Completed NCT04351334 - Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Active, not recruiting NCT02416739 - Anticancer Activity of Nicotinamide on Lung Cancer Phase 2/Phase 3
Completed NCT00444015 - Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) Phase 1
Completed NCT00105092 - Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. Phase 2